Regenxbio
Regenxbio's revenue rose 104.5% to $170 million in fiscal 2025. Its operating margin was −94.6%, up from −280.0% a year earlier. Free cash flow was −$126 million. The diluted share count rose 4.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Regenxbio does
Regenxbio develops gene therapies: one-time treatments that deliver a working gene into a patient's cells using harmless, modified viruses called AAV vectors. All of its therapies are built on its NAV Technology Platform, which it has held exclusive rights to since 2009. It focuses on retinal, neuromuscular and neurodegenerative diseases and makes its own therapies in U.S. facilities.
It has no product of its own on the market. It is developing a treatment for wet age-related macular degeneration and diabetic retinopathy with AbbVie, a treatment for Duchenne muscular dystrophy called RGX-202, and treatments for two inherited disorders, MPS II and MPS I, with Nippon Shinyaku. The FDA has issued a Complete Response Letter for the MPS II application, and has put clinical holds on both MPS programs.
For many years it also earned money by licensing its vectors to other drug makers. Licensees use them in programs such as Novartis's gene therapies for spinal muscular atrophy. At the end of February 2026 it had 371 full-time employees, most of them in research and development.
Its biggest risks, as it describes them
- Clinical holds and a Complete Response Letter from the FDA may delay or end its MPS programs.
- It expects to keep losing money, has never sold a product, and its cash may not cover the next 12 months.
- Gene therapies are new, complex and hard to make, and it relies on third parties for some materials and testing.
- Its trials may fail to show safety or effectiveness, or may cause serious side effects.
- Its success depends partly on its licensing and collaboration partners such as AbbVie.
Income statement
From fiscal 2018 to 2021, earnings per share grew 2.2% a year and net income 8.6% a year, as new shares raised the share count by 20% and diluted each share's earnings. Regenxbio then lost money in fiscal 2022, 2023, 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 849 | 565 | 314 | 245 | 241 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | 6.1x | −11.3x | −39.1x | −18.4x | −3.6x |
| Current ratio | 4.0x | 3.2x | 2.6x | 2.7x | 2.4x |
| Quick ratio | 4.0x | 3.2x | 2.6x | 2.7x | 2.4x |
Cash flow
Projections
Project Regenxbio's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Regenxbio reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −273.0% | −218.3% | 30.4% |
| Altman Z'' | −3.56 | −6.10 | −7.82 |
| Accruals ratio | −6.4% | −10.4% | −15.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | — |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Regenxbio side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Regenxbio | FY25 | 104.5% | −94.6% | −74.2% | — | — | — | |
| Beam Therapeutics | FY25 | 120.0% | −274.6% | −257.6% | — | — | — | Compare |
| Xencor | FY25 | 13.7% | −141.3% | −110.1% | −19.9% | — | 3 | Compare |
| Monte Rosa Therapeutics | FY25 | 63.5% | −43.8% | −22.2% | — | — | — | Compare |
| Arcus Biosciences | FY25 | −4.3% | −156.3% | −195.9% | — | — | 0 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 5 | 10 | 218 | 35 | 155 | 470 | 113 | 90 | 83 | 170 |
| Revenue growth | −39.5% | 126.5% | 2,002.4% | −83.9% | 338.7% | 204.3% | −76.0% | −19.9% | −7.7% | 104.5% |
| Gross profit | 4 | 9 | 209 | 27 | 119 | 418 | 58 | 53 | 50 | — |
| Research and development | 46 | 57 | 84 | 124 | 166 | 181 | 242 | 232 | 208 | 228 |
| Operating income | −65 | −76 | 88 | −149 | −119 | 160 | −263 | −268 | −233 | −161 |
| Net income | −63 | −73 | 100 | −95 | −111 | 128 | −280 | −264 | −227 | −194 |
| Diluted EPS (US$) | −2.38 | −2.45 | 2.73 | −2.58 | −2.98 | 2.91 | −6.50 | −6.02 | −4.59 | −3.76 |
| Diluted shares (millions) | 26 | 30 | 37 | 37 | 37 | 44 | 43 | 44 | 50 | 52 |
| Cash flow | ||||||||||
| Cash from operations | −49 | −58 | 105 | −108 | −54 | 219 | −208 | −218 | −173 | −124 |
| Capital expenditure | 8 | 7 | 13 | 12 | 27 | 84 | 31 | 10 | 2 | 2 |
| Free cash flow | −57 | −65 | 91 | −119 | −81 | 135 | −238 | −228 | −176 | −126 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 7 | 11 | 17 | 27 | 32 | 39 | 41 | 40 | 38 | 35 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 159 | 176 | 471 | 400 | 522 | 849 | 565 | 314 | 245 | 241 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 173 | 199 | 544 | 498 | 708 | 1,114 | 833 | 574 | 466 | 453 |
| Total liabilities | 11 | 16 | 35 | 48 | 330 | 350 | 317 | 262 | 206 | 350 |
| Shareholders' equity | 162 | 183 | 509 | 450 | 378 | 764 | 516 | 312 | 260 | 103 |
| Margins and ratios | ||||||||||
| Gross margin | 97.9% | 83.6% | 95.6% | 76.6% | 76.9% | 89.0% | 51.6% | 58.8% | 59.7% | — |
| Operating margin | −1,423.8% | −730.1% | 40.3% | −422.9% | −77.1% | 34.0% | −233.2% | −297.1% | −280.0% | −94.6% |
| Net margin | −1,372.1% | −704.0% | 45.7% | −268.9% | −72.0% | 27.2% | −248.7% | −292.0% | −272.5% | −113.8% |
| Free cash flow margin | −1,235.7% | −626.9% | 41.8% | −339.0% | −52.4% | 28.6% | −211.3% | −253.1% | −210.7% | −74.2% |
| Rule of 40 (growth + FCF margin) | −1,275.2% | −500.4% | 2,044.2% | −422.8% | 286.3% | 232.9% | −287.4% | −273.0% | −218.3% | 30.4% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −33.3% | −42.5% | 28.9% | −19.8% | −26.9% | 22.4% | −43.8% | −63.6% | −79.5% | −107.0% |
| Return on assets | −31.9% | −39.4% | 26.9% | −18.2% | −18.4% | 14.0% | −28.8% | −37.5% | −43.7% | −42.2% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |